← Back to Search

Be Vape Free Curriculum for Preventing Vaping

N/A
Waitlist Available
Led By Bonnie Halpern-Felsher, Ph.D.
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to follow-up at approximately 156 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether the Be Vape Free curriculum is effective in preventing tobacco use among middle and high school students.

Who is the study for?
This trial is for middle and high school students who are currently receiving health education at schools that have chosen to participate in the study. There are no specific exclusion criteria, so all students in these settings can potentially join.
What is being tested?
The trial is testing the 'Be Vape Free' curriculum from Stanford's Tobacco Prevention Toolkit. It aims to see if this online program helps reduce positive attitudes towards e-cigarettes, prevents tobacco use, and changes actual tobacco usage among students.
What are the potential side effects?
Since this intervention involves educational material rather than a medical treatment, there aren't any direct physical side effects. However, it may change students' perceptions and behaviors regarding vaping and tobacco use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to follow-up at approximately 156 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to follow-up at approximately 156 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in e-cigarette use
Change in intention to use of e-cigarettes scaled score as measured by investigator-originated survey

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Receives Stanford vaping prevention curriculum (randomized phase)Experimental Treatment1 Intervention
Stanford vaping prevention curriculum is administered.
Group II: Receives Stanford vaping prevention curriculum (pilot phase)Experimental Treatment1 Intervention
Stanford vaping prevention curriculum is administered as pilot arm preceding main experimental intervention.
Group III: Does not receive Stanford vaping prevention curriculum (randomized phase)Active Control1 Intervention
Receives another curriculum or no vaping prevention education.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,472 Previous Clinical Trials
17,491,018 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,925 Previous Clinical Trials
41,007,201 Total Patients Enrolled
1 Trials studying E-Cigarette Use
40 Patients Enrolled for E-Cigarette Use
Bonnie Halpern-Felsher, Ph.D.Principal InvestigatorStanford University
1 Previous Clinical Trials
600 Total Patients Enrolled

Media Library

Stanford Vaping Prevention curriculum Clinical Trial Eligibility Overview. Trial Name: NCT05493982 — N/A
E-Cigarette Use Research Study Groups: Does not receive Stanford vaping prevention curriculum (randomized phase), Receives Stanford vaping prevention curriculum (randomized phase), Receives Stanford vaping prevention curriculum (pilot phase)
E-Cigarette Use Clinical Trial 2023: Stanford Vaping Prevention curriculum Highlights & Side Effects. Trial Name: NCT05493982 — N/A
Stanford Vaping Prevention curriculum 2023 Treatment Timeline for Medical Study. Trial Name: NCT05493982 — N/A
~2090 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top